Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VX-561 in Adults With Cystic Fibrosis
2018-003970-28Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deutivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change in ppFEV1 from baseline at Week 12. Started Apr 2019; status: completed.
02
Drugs
deutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-003970-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003970-28.